Status:
COMPLETED
Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)
Lead Sponsor:
Viralytics
Conditions:
Malignant Melanoma
Eligibility:
All Genders
21-70 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the safety of an injection of coxsackievirus A21 into a melanoma tumour, and also to see if there is a tumour response.
Detailed Description
Coxsackievirus A21, a naturally occurring enterovirus, has shown that in vivo it can infect and lyse melanoma. This study is to assess safety of a single intratumoural injection of the virus into an a...
Eligibility Criteria
Inclusion
- stage IV melanoma (AJCC classification)
- minimum of 2 sc metastases
- failure or refusal of standard chemotherapy
- ECOG score of 0 or 1
- other
Exclusion
- metastatic CNS disease
- ocular or mucosal melanoma
- immunodeficiency
- splenectomy
- other
Key Trial Info
Start Date :
November 8 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 21 2006
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00235482
Start Date
November 8 2005
End Date
April 21 2006
Last Update
June 27 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Melanoma Unit, Mater Misericordiae Hospital
Newcastle, New South Wales, Australia, 2298